Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in…
2 analysts rate SER Buy on consensus.
Consensus price target: $9.50 (+475.76% upside from $1.65)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Brannan Stephen K. director | Jul 7, 2026 | Purchase | 1,000 | $2.03K |
| Marshall Richard Peter director | May 19, 2026 | Purchase | 12,183 | $20.1K |
| Moreadith Randall Chief Scientific Officer | Mar 23, 2026 | Sale | 6,500 | $18.57K |
| Moreadith Randall Chief Scientific Officer | Mar 19, 2026 | Sale | 39,000 | $97.5K |
| Moreadith Randall Chief Scientific Officer | Feb 2, 2026 | Sale | 6,500 | $19.68K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | -100% | $-19.18M |
| 2024 | $56K | -98.22% | $-11.14M |
| 2023 | $3.15M | +530.6% | $5.27M |
Stock data for SER: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics